Autoinoculation versus intralesional injection of bleomycin in the treatment of multiple recalcitrant warts

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR201803003151322

Enrollment

Registered

2018-02-27

Start date

2017-02-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urological and Genital Diseases Human papilloma virus causing warts

Interventions

Autoinoculation group

Intralesional injection of bleomycin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - patients with multiple recalcitrant warts. -patients with age ranged from 18 ¿ 45 years. -Both sexes were involved in this study. -The individual patient may have multiple types of warts at different sites i.e.one patient may have palmoplantar warts and genital warts and we treated both types in two different sites in the same patient.

Exclusion criteria

Exclusion criteria: -patients having other dermatological diseases. -pregnant and lactating females,children. -immunosuppressed individuals. -patient with koebner phenomenon. -patient with HCV or HIV. -patient on aspirin or anticoagulant therapy. -patient with bleeding tendency. -patient with lung diseases( in bleomycin treated group). -patients with mucosal warts.

Design outcomes

Primary

Measure	Time frame
is to compare the efficacy and safety of autoincuolation versus intralesional injection of bleomycin in warts treatment.	—

Secondary

Measure	Time frame
to detect the remote clinical response remote nonmanipulated warts	—

Countries

Egypt

Contacts

Public ContactMohamed Ibrahim ElGhareeb ElGanainy

lecturer of dermatology

moh_elghareeb@yahoo.com00201092907455

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026